Janssen Stands Ready To Beat Its Peers, Despite Biosimilars
This article was originally published in The Pink Sheet Daily
J&J expects above industry-average growth through 2019; long-term growth plans were outlined during an analyst day May 20. The strategy depends on new indications for high priority medicines and new launches, with 12 eventual blockbusters to come through 2019.
You may also be interested in...
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.